Walt Disney Co vs McKesson Corporation — how do they compare? Walt Disney Co trades at $107.29 (market cap $184.79B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: Walt Disney Co is the larger of the two by market cap, and Walt Disney Co pays the higher dividend (1.4%). Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and McKesson Corporation for 74 Days on average.
| DIS | MCK | |
|---|---|---|
Market Cap | $184.79B | $108.46B |
Volume | 13,033,550 | 712,607 |
Sector | Media | Health |
52-Week High | $116.65 | $995.69 |
52-Week Low | $92.40 | $725.17 |
Typical Hold Time | 199 Days | 74 Days |
Enterprise Value | $225.65B | $115.00B |
Dividend Yield | 1.4% | 0.4% |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.93% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $91.4B to $94.4B in 2025 and net income surging to $12.4B. Recent earnings beats and a $60B parks investment highlight strategic expansion. Analyst consensus remains strongly positive with a $125.67 price target, representing 17% upside potential from current levels.
Disney presents a compelling investment opportunity with accelerating profitability and strategic investments in experiences and streaming. Key risks include free cash flow pressure from elevated capital expenditures and competitive streaming landscape challenges. The stock's current valuation at 21.6x P/E appears reasonable given growth trajectory, though execution on content investments and margin expansion will be critical for sustained outperformance.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →